Trial Profile
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Single Dose Study of the Pharmacokinetics (PK), Pharmacodynamics (PD) and Safety of Intravenous and Subcutaneous CDP6038 in Subjects With Rheumatoid Arthritis on Stable Methotrexate.
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Olokizumab (Primary) ; Olokizumab (Primary) ; Methotrexate
- Indications Rheumatoid arthritis
- Focus Adverse reactions; Biomarker; Pharmacodynamics; Pharmacokinetics
- Sponsors UCB Pharma Inc
- 14 Nov 2012 Results presented at the 76th Annual Scientific Meeting of the American College of Rheumatology and the 47th Annual Meeting of the Association of Rheumatology and Health Professionals.
- 29 Sep 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 09 Aug 2010 Planned end date changed from 1 Aug 2010 to 1 Sep 2010 as reported by ClinicalTrials.gov.